NOVOCURE
Novocure, a commercial stage oncology company, announced today that the last patient has been enrolled in the PANOVA trial, an open-label phase II clinical trial of Tumor Treating Fields (TTFields) together with gemcitabine in twenty patients with newly-diagnosed advanced pancreatic adenocarcinoma. In light of the rapid conclusion of enrollment, the absence of serious safety concerns, to date, and following a request by study physicians, Novocure will expand the trial to include an additional study cohort of twenty patients who will be treated with concomitant TTFields, gemcitabine and nab-paclitaxel.
“PANOVA is the first clinical study testing TTFields in pancreatic cancer,” said Uri Weinberg, MD, PhD, Vice President, Research and Development of Novocure. “We thank the first twenty patients and their physicians for participating in the trial. Since the safety profile, to date, on this protocol has been in line with previous clinical experience in other indications, we plan to test the combination of TTFields with gemcitabine and nab-paclitaxel in an additional cohort of patients. We hope to see the same synergistic effect that was demonstrated in preclinical models when TTFields therapy was combined with taxane-based chemotherapy.”
“We are proud to take part in a clinical trial testing a novel approach for the treatment of pancreatic cancer,” said Fernando Rivera, MD, Senior Medical Oncologist at the Santander University Hospital in Spain, who has treated five patients under the PANOVA protocol. “This regional, non-invasive treatment that acts on dividing cancer cells has the potential to make a real change in the treatment paradigm for many of the 340,000 patients diagnosed with pancreatic cancer worldwide every year, mostly at an advanced, non-curable stage. As the first cohort demonstrated that TTFields is well-tolerated by patients, we should now investigate TTFields in combination with gemcitabine and nab-paclitaxel, which is a new standard therapy in advanced pancreatic cancer.”
“Novocure is committed to studying TTFields in solid tumor cancers,” said Asaf Danziger, Chief Executive Officer of Novocure. “Novocure is currently running clinical trials testing the safety and efficacy of TTFields in pancreatic cancer, glioblastoma, brain metastasis from lung cancer and ovarian cancer. Additional clinical trials testing TTFields alone or together with standard of care chemotherapy will be initiated during 2015.”
About the PANOVA Trial
PANOVA is an open-label phase II clinical trial designed to test the safety and preliminary efficacy of TTFields therapy together with gemcitabine for the first line treatment of pancreatic adenocarcinoma. Following regulatory approval, PANOVA will enroll an additional cohort of twenty patients in Spain, Germany and Switzerland investigating TTFields in combination with gemcitabine and nab-paclitaxel. For more information please refer to www.clinicaltrials.gov .
About Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States and Europe. Prognosis is poor, with a five-year overall survival rate of 5% for all cases, as close to 85% of patients will be diagnosed with advanced, non-resectable disease. Recently, albumin-bound pactlitaxel (nab-paclitaxel) combined with gemcitabine has demonstrated a statistically significant survival benefit compared to gemcitabine alone, making it a new treatment option for advanced pancreatic cancer.
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates a low intensity, alternating electric fields within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.
About Novocure
Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com .
Contact:
Novocure
Ashley Cordova, 212-767-7558
acordova@novocure.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum